Targeted reduction of CCR4+ cells is sufficient to suppress allergic airway inflammation

Abstract Back ground Bronchial asthma is characterized by allergic airway inflammation involving C-C chemokine receptor type 4 (CCR4)-positive Th2 cells. As such, we hypothesize that the disease can be alleviated by targeted-elimination of CCR4+ cells. Thymus and activation-regulated chemokine (TARC...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Respiratory investigation 2013-12, Vol.51 (4), p.241-249
Hauptverfasser:	Honjo, Akifumi, Ogawa, Hirohisa, Azuma, Masahiko, Tezuka, Toshifumi, Sone, Saburo, Biragyn, Arya, Nishioka, Yasuhiko
Format:	Artikel
Sprache:	eng
Schlagworte:	Airway Resistance - drug effects Animals Asthma - drug therapy Asthma - etiology Asthma - genetics Asthma - immunology Bronchial Hyperreactivity - drug therapy Bronchial Hyperreactivity - etiology Chemokine CCL17 - pharmacology Chemokine CCL17 - therapeutic use Disease Models, Animal Exotoxins - pharmacology Exotoxins - therapeutic use Female Immunoglobulin E - blood Internal Medicine Lung - cytology Lung - immunology Mice Mice, Inbred BALB C Molecular Targeted Therapy Pulmonary/Respiratory Pyroglyphidae - immunology Receptors, CCR4 Recombinant Fusion Proteins - pharmacology Recombinant Fusion Proteins - therapeutic use Th1 Cells - immunology Th2 Cells - immunology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!